On March 22, 2022, Affini-T Therapeutics, Inc., a biotechnology company unlocking the power of T cells against oncogenic driver mutations, announced the completion of an oversubscribed $175 million financing co-led by Vida Ventures and Leaps by Bayer, the impact investment unit of Bayer. Additional investors participating in the round include Humboldt Fund, The Parker Institute for Cancer Immunotherapy, Catalio Capital Management, Agent Capital, Alexandria Venture Investments, Erasca Ventures, Fred Hutchinson Cancer Research Center, and other leading blue chip life science investors. Wilson Sonsini Goodrich & Rosati advised Affini-T Therapeutics on patent matters related to the transaction.

With proceeds from this financing, the company will operationalize its platform discovery engine and seek to drive multiple oncogene driver programs into the clinic while pursuing complementary technology licenses to bolster its cell therapy platform. The company has established a bi-coastal U.S. presence with research labs in Seattle, Washington, and headquarters and manufacturing infrastructure in Boston, Massachusetts, to enable and accelerate growth.

The Wilson Sonsini team that advised Affini-T on patent matters related to the transaction included Vern Norviel, Rona Lamiquiz, and Brandon Tavshanjian.

For more information, please see Affiniti-T's press release.